Stock Screener App

Frei -

Installieren

0.7816

1.23% -0.0097

after-market

Handel nachbörslich: .78 -0.0016 -0.20%

Rein Therapeutics Inc (RNTX)

Überblick Nachrichten Preisverlauf Forum Prognose

Rein Therapeutics Inc Aktie (RNTX) Neueste Nachrichten

Rein Therapeutics Inc (RNTX) Cash Flow - TradingKey

Rein Therapeutics Inc (RNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Rein Therapeutics Inc (RNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Rein Therapeutics Inc (RNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

RNTX|Rein Therapeutics Inc|Price:0.791|Chg%:-0.009 - TradingKey

Rein Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNTX - TradingView

Rein Therapeutics (RNTX) Proxy filing Summary - Quartr

Rein Therapeutics (RNTX) Q4 2025 earnings summary - Quartr

Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm

symbol__ Stock Quote Price and Forecast - CNN

Rein Therapeutics Shareholders Approve Governance and Stock Changes - TipRanks

Rein Therapeutics expands phase 2 IPF trial to Germany By Investing.com - Investing.com South Africa

Rein Therapeutics expands phase 2 IPF trial to Germany - Investing.com

Rein Therapeutics Completes Global Expansion of Phase 2 IPF Trial - marketscreener.com

Rein Therapeutics expects initial lung-trial data in 2H 2026 - Stock Titan

Rein Therapeutics Price Target Announced at $4.00/Share by Maxim Group - Moomoo

Rein Therapeutics (RNTX) Gains Buy Rating and $4 Price Target fr - GuruFocus

RNTX Initiates Coverage On by Maxim Group -- Rating Set to Buy - GuruFocus

Rein Therapeutics (RNTX) AGM 2026 Summary - Quartr

Transcript : Rein Therapeutics Inc.Shareholder/Analyst Call - marketscreener.com

RNTX: All agenda items, including director elections and share authorization, were approved - TradingView

RNTX: All agenda items, including director elections and share increase, were approved - TradingView

Rein Therapeutics (RNTX) Slips 1.78% as Stock Nears Key Support LevelMcClellan Summation - DonanımHaber

Price to sales forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView

Enterprise value to EBITDA forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView

Enterprise value to revenue forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView

Price to earnings forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView

Price to earnings forward of Rein Therapeutics, Inc. – BOATS:RNTX - TradingView

Price to sales forward of Rein Therapeutics, Inc. – BOATS:RNTX - TradingView

Enterprise value to EBIT forward of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView

Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Cash Management Improves - dars.gov.et

RNTXRein Therapeutics Inc Latest SEC Filings - Finviz

Rein Therapeutics Inc.(NasdaqCM:RNTX) added to Russell Microcap Value Benchmark Index - marketscreener.com

Rein Therapeutics Inc.(NasdaqCM: RNTX) added to Russell 3000E Value Benchmark - marketscreener.com

Rein Therapeutics, Inc Actuals & Estimates (NASDAQ:RNTX) - TradingView

RNTX Forecast — Price Target — Prediction for 2027 - TradingView

Rein Therapeutics Inc (RNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Rein Therapeutics Inc (RNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey

Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Narrower‑than‑expected loss as clinical pipeline advances - dars.gov.et

Rein Therapeutics Inc (RNTX) Institutional Confidence - TradingKey

Rein Therapeutics (RNTX) Surges 5.87% as Stock Tests Key Resistance at $0.97Sweep Order Flow - DonanımHaber

RNTX Q1 2026 Earnings: Smaller-Than-Expected Loss Drives Positive Stock ReactionFinal Results - dars.gov.et

Rein Therapeutics Inc (RNTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Rein Therapeutics Inc (RNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Rein Therapeutics Inc (RNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy - Yahoo Finance

Rein Therapeutics enrolls 16 patients in lung fibrosis trial By Investing.com - Investing.com Nigeria

Rein Therapeutics (RNTX) Slips 1.6% as Stock Tests Key Support at $0.89Small Cap Breakouts - newsline.com

RNTX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Stock HigherPost-Earnings Reaction - newsline.com

Rein Therapeutics enrolls 16 patients in lung fibrosis trial - Investing.com

Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewswire

IPF trial for LTI-03 adds first UK patient, expands to 3 countries - Stock Titan

RNTX Q1 2026 Earnings: Significant EPS Beat Highlights Cost Discipline as Pre-Revenue Biotech Advances PipelineInterim Report - newsline.com

Rein Therapeutics Inc. (RNTX) Q1 2026 Earnings: Better-than-Expected Loss Highlights Cost DisciplineEarnings Miss Streak - dars.gov.et

Rein Therapeutics (NASDAQ: RNTX) 2026 proxy outlines share boost, director elections, pay - Stock Titan

RNTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

H.C. Wainwright cuts Rein Therapeutics stock price target on dilution By Investing.com - Investing.com Canada

H.C. Wainwright Maintains Rein Therapeutics(RNTX.US) With Buy Rating, Cuts Target Price to $8 - Moomoo

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Rein Therapeutics (RNTX) Holds Steady at $1.11, Testing Key SupportLow Vol Factor - dars.gov.et

BNTX

$91.09

1.97%

INCY

$118.87

1.02%

ROIV

$34.72

0.83%

RPRX

$58.73

0.17%

ONC

$325.90

0.00%

ALNY

$278.40

2.44%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters